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Section of Endocrinology, Dipartimento Biomedico di Medicina Interna e Specialistica, University of
Palermo, 90127 Palermo, Italy
Context: The visceral adiposity index (VAI) has proved to be a marker of visceral adipose dysfunc-
tion, strongly associated with insulin sensitivity in both the general and specific populations of
patients at metabolic risk.
Objective: The objective of the study was to test VAI as a useful tool to assess early metabolic risk
in acromegaly.
Patients: Twenty-four newly diagnosed acromegalic patients (11women and 13men, aged 54.9
13.6 yr) were grouped into those with normal (group A, n  13, 54.2%) and those with high VAI
(group B, n  11, 45.8%).
Outcome Measures: Glucose, hemoglobin A1c, nadir and area under the curve (AUC) of GH
(AUCGH) during the oral glucose tolerance test, AUCCpeptide during amixed-meal tolerance test, M
value during euglycemic-hyperinsulinemic clamp, oral dispositional index (DIo), each component
of the metabolic syndrome, leptin, adiponectin, TNF-, and IL-6.
Results: The VAI value was positively correlated with the age of patients (  0.408; P  0.048),
tumor volume (0.638;P0.001), basalGH (0.622;P0.001), nadirGH (0.534;P0.007),
AUCGH (  0.603; P  0.002), IGF-I (  0.618; P  0.001), TNF- (  0.512; P  0.010), and
AUCCpeptide ( 0.715; p0.001) and negatively with adiponectin (0.766; P 0.001), M value
(0.818;P0.001), andDIo (0.512;P0.011). PatientswithhighVAI showedsignificantly
higherbasalGH levels (P0.018),AUCGH (P0.047), IGF-I (P0.047),AUCCpeptide (P0.018), lower
M value (P  0.001), DIo (P  0.006), and adiponectin levels (P  0.001), despite the absence of a
significantly higher prevalence in the overt metabolic syndrome and glucose tolerance abnormal-
ities. AUCGH proved to be the main independent factor influencing VAI.
Conclusions: In acromegaly, VAI appears to be associated with disease activity, adiponectin levels,
and insulin sensitivity and secretion and is influenced independently by GH levels. VAI could there-
fore be used as an easy and useful new tool in daily clinical practice for the assessment of early
metabolic risk associated with active acromegaly. (J Clin Endocrinol Metab 97: 2907–2915, 2012)
Growth hormone (GH) is a counterregulatory hor-mone that antagonizes the hepatic and peripheral
metabolic effects of insulin, involving the stimulation of
gluconeogenesis and lipolysis, which results in increased
blood glucose and free fatty acid levels (FFA) (1, 2). GH
mainly exerts its lipolytic effect in adipose tissue, by in-
creasing adipose tissue hormone-sensitive lipase activity
and resulting in an alteration in adipose tissue distribution
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and increased FFA flux from adipose to peripheral tissues
(3). In acromegaly, the lipolytic and insulin-antagonistic
effects of GH may alter adipose tissue distribution. In-
creasingGH/IGF-I levels are associatedwitha smaller pro-
portion of total adipose tissue, and a negative correlation
between insulin sensitivity and sc, im, and total adipose
tissue was detected (4). Recently, we proposed a sex-spe-
cific mathematical index, the visceral adiposity index
(VAI), based on simple anthropometric andmetabolic pa-
rameters, as a surrogate marker of adipose tissue function
and distribution independently correlated with cardio-
metabolic risk in the general population (5). VAI showed
a strong association with both insulin sensitivity (evalu-
ated with a euglycemic-hyperinsulinemic clamp) and vis-
ceral adipose tissue [measured with magnetic resonance
imaging (MRI)] (5). Furthermore, circulating concentra-
tions of inflammatory adipocytokines are recognized tobe
the most important factor in causing and maintaining in-
sulin resistance (IR) aswell as a rise inFFA levels (6). Inour
hypothesis, insulin sensitivity, lipolytic activity, and adi-
pocytokine production, which play amain role in the gen-
esis of cardiovascular sequelae in the general population
(7–9), may be indirectly represented by VAI. The aim of
this study was to test VAI as a useful new tool to assess
earlymetabolic risk inpatientswithactive acromegaly and
to evaluate its association with adipocytokine levels and
insulin sensitivity and secretion parameters.
Patients and Methods
For the purpose of the study, we enrolled 24 patients (13 males
and 11 females; aged 54.9 13.6 yr, range 33–78 yr) with active
newly diagnosed acromegaly, who presented at the Endocrinol-
ogy Section of the University of Palermo from January 1, 2004,
to December 31, 2011. Patients with mixed GH/prolactin-se-
creting adenoma, previously treated with acromegaly therapy
(surgery, somatostatin analogs, dopamine agonist, or pegviso-
mant) or with deficiency of one or more anterior pituitary hor-
mones were excluded from this study. Activity of disease at the
time of the study was confirmed by plasma mean GH profile,
elevated age- and gender-corrected plasma IGF-I levels, andnon-
suppressible GH after an oral glucose tolerance test (OGTT)
(10). In all patients,MRI scan revealed the presence of a pituitary
tumor. Tumor volume was calculated in line with the Di Chiro
and Nelson formula (volume height lengthwidth /6)
andwas expressedas cubicmillimeters.Themeandurationof the
disease was established by patient interview, patient clinical pic-
tures, and onset of osteoarticular symptoms. At the time of hos-
pitalization, all patients signed a consent form for the scientific
use of their data after a full explanation of the purpose of the
study. This study was approved by the Institutional Review
Board of the Faculty ofMedicine, University of Palermo, and the
identity of the participants remained anonymous during data-
base analysis.
Study design
Body mass index (BMI), waist circumference (WC), systolic
blood pressure (SBP), and diastolic blood pressure (DBP) were
measured in all patients. WC was measured at the midpoint
between the lower rib and the iliac crest. After an overnight fast,
lipid profile [total, high-density lipoprotein (HDL), and low-
density lipoprotein (LDL) cholesterol and triglycerides (TG)],
hemoglobin A1c (HbA1c), mean fasting plasma GH (at least
three blood samples at 30-min intervals), and IGF-I levels were
measured. To normalize IGF-I for age in individual patients, we
calculated the ratio between the IGF-I level and the upper limit
of the normal (ULN) range for age (normal1), and the data are
presented as IGF-I ULN. OGTT was performed by measuring
plasmabloodglucose, insulin, andGHlevels every 30min for 2h
after a75-goral glucose load, and theareaunder the curve (AUC)
of GH (AUCGH) was calculated. Insulin sensitivity was tested
with the euglycemic-hyperinsulinemic clamp (11). The clamp
was performed under standard conditions, i.e. infusion of an
insulin priming of 160mU/m2 body surface for the first 4 min of
the test, followed by 40 mU/m2 for the remaining 116 min; the
rate of peripheral glucose utilization (Mvalue)was calculated by
dividing the glucose amount infused during the last 40 min by
body weight measured in kilograms (milligrams per kilogram
per minute). Under the steady-state conditions of euglycemia,
the glucose infusion rate equals glucose uptake by all the tis-
sues in the body and is therefore a measure of tissue sensitivity
to exogenous insulin. -Cell function was accurately and di-
rectly determined by measuring serum C-peptide levels before
and after the standard mixed-meal tolerance test (MMTT)
(12). A liquid meal (6 mg/kg up to a maximum of 360 ml) of
Ensure Plus (25 g protein, 80.8 g carbohydrate, 20.6 g fat) was
given after a 12- to 14-h overnight fast. Bloodwas drawn every
30 min for 120 min during the MMTT for the determination
of glucose and C-peptide levels, and the AUC of C-peptide
(AUCCpeptide) was calculated. In addition, -cell function rel-
ative to insulin sensitivity, assessed by oral disposition index
(DIo) (13), was evaluated.
Toavoid significant gaps in timebetween the various tests,we
routinely applied to all subjects our internal protocol of man-
agement of newly diagnosed acromegalic patients, which per-
forms theOGTTduring first access (baseline). If the diagnosis of
acromegaly is confirmed, we plan the euglycemic-hyperinsuline-
mic clamp 1 wk after the baseline and theMMTT 2wk after the
baseline.VAIwas calculated asdescribed (5), using the following
formulas differentiated according to sex, where TG levels are
expressed in millimoles per liter and HDL is HDL-cholesterol
levels expressed in millimoles per liter: for males, VAI  [WC/
39.68 (1.88BMI)] (TG/1.03) (1.31/HDL); for females,
VAI [WC/36.58 (1.89BMI)] (TG/0.81) (1.52/HDL).
According to specific age-stratified cutoff points of VAI iden-
tifying patients with presumed visceral adipose dysfunction and
cardiometabolic risk (14), we divided the patients into two
groups: those with normal (group A, 13 patients) and those with
highVAI (groupB, 11patients). The appropriate cutoff points of
VAI used were the following: 2.52 for subjects under 30 yr, 2.23
for those aged between 30 and 42 yr, 1.92 between 42 and 52 yr,
1.93 between 52 and 66 yr, and 2.00 for subjects over 66 yr. In
addition, to obtain better evaluation of adipose function, in all
patients we measured serum levels of four circulating adipocy-
tokines: leptin, adiponectin, IL-6, and TNF-. All samples (for
glycemia, HbA1c, lipid profile, insulin, C-peptide, GH, and
2908 Ciresi et al. Visceral Adiposity Index and Acromegaly J Clin Endocrinol Metab, August 2012, 97(8):2907–2915
IGF-I) were immediately analyzed after the tests were performed
in each individual after an overnight fast. Serum samples to be
used for the adipocytokine determinations were kept frozen at
20 C until assayed at the end of the study.
Patients with a previous diagnosis of diabetes mellitus, al-
ready treated, were excluded from this study to avoid the impact
of the treatment on metabolic parameters and because of their
inability to perform theOGTT. At the time of the study, patients
diagnosed after the OGTT as having impaired fasting glucose
(IFG) or impaired glucose tolerance (IGT) were treated with a
controlled diet only after the completion of the study design to
avoid the impact of strict adherence to diet on the results of the
study and to evaluate the main role of GH on metabolic param-
eters. No patients with previous diagnosis of IFG or IGT re-
cruited in the study were already receiving dietary or pharma-
cological treatment.
Among the patients affected by increased blood pressure,
those with a previous diagnosis of hypertension (70%) received
pharmacological treatment with sartans (58%) or angiotensin-
converting-enzyme inhibitors (42%). The patients diagnosed as
having systolicordiastolichypertension for the first timeat the time
of thediagnosisofacromegalydidnotreceiveanyspecific treatment
until the end of the study design period (2 wk), during which they
underwent intensive blood pressure control.
Among the dyslipidemic patients, those with a previous di-
agnosis (43%) had never received specific treatment. We first
diagnosed dyslipidemia in four patients who had never received
any dietary or pharmacological treatment until the end of the
study protocol to avoid the impact of the treatment onmetabolic
parameters.
Hormone and biochemical assays
All biochemical data were collected after overnight fasting.
Glycemia, HbA1c, and lipid levels were measured in our cen-
tralized accredited laboratory with standard methods. During
the entire study period, GH samples from all subjects were run
in the same immunoradiometric assay (Radium, Pomezia, Italy).
The sensitivity of the assayswas 0.05g/liter. The average intra-
and interassay coefficients of variation (CV)were 4.5 and 7.9%,
respectively. Serum IGF-I was measured using immunoradio-
metric assays (Diagnostic System Laboratories Inc., Webster,
TX). The normal ranges (for age) were 180–625 and 151–530
(20), 118–475 and 118–450 (21–30), 102–400 and 100–390
(31–40), 100–306 and 96–228 (41–50), 95–270 and 90–250
(51–60), 88–250and82–200 (61–70), and78–200and68–188
(70) g/liter for men and women, respectively. The sensitivity
of the assay was 0.8 g/liter. The intra- and interassay CV were
3.4, 3.0, and 1.5%and 8.2, 1.5, and 3.7% for low,medium, and
high points on the standard curve, respectively.
Serum insulin was measured by ELISA (DRG Instruments
GmbH, Marburg, Germany). The sensitivity of the method was
1 IU/ml. The normal insulin range was 5–19 IU/ml. Serum C-
peptide was measured by ELISA (DRG Instruments). The sen-
sitivity of themethodwas 0.064 ng/ml. The intra- and interassay
CV were 5.1–6.7% and 8.3–9.9%, respectively. The assays for
the assessment of IGF-I, insulin, and C-peptide were constant
during the entire period of the study. Circulating leptin and adi-
ponectin were measured using ELISA kits from SPI bio (Mon-
tigny le Bretonneux, France). For leptin, the limit of sensitivity
was 0.5 ng/ml, and the intra- and interassay CV were 3.0–7.5
and 3.2–9.2% at leptin levels of 3.5–25.5 and 5.4–25.1 ng/ml,
respectively. For adiponectin, the limit of sensitivity was 0.7 g/
ml, and the intra- and interassayCVwere6.4–7.0 and7.3–8.2%
at adiponectin levels of 7.1–21.1 and 5.2–17.7 g/ml, respec-
tively. TNF- was measured by ELISA (Amersham human
TNF-, Biotrak Easy ELISA; GE Healthcare, Piscataway, NJ).
The sensitivity of the method was 2.5 pg/ml. The overall intra-
and interassay CV were 6.0 and 9.3%, respectively. IL-6 was
measured by ELISA (human IL-6 ultrasensitive; Invitrogen,
Camarillo, CA). The sensitivity of the method was less than 104
fg/ml. The intra- and interassay CVwere 4.7–8.3 and 6.7–10%,
respectively.
Statistical analysis
The Statistical Packages for Social Sciences SPSS version 17
was used for data analysis. Baseline characteristics were pre-
sented as mean  SD or as median and interquartile range for
continuous variables; rates and proportions were calculated for
categorical data. The normality of distribution of the quantita-
tive variables was assessed by means of the Kolmogorov-Smir-
nov test). The differences between the two groups of patients
(with normal or high VAI) were evaluated with theMann-Whit-
ney U test. Simple univariate correlations among continuous
variables without normal distribution were determined by
Spearman’s test, the nonparametric equivalent for Pearson’s test.
To evaluate the independent variables influencing the VAI in all
acromegalic patients, a linear regression model was performed.
A P value 0.05 was considered statistically significant.
Results
The clinical and biochemical features of patients are
shown in Table 1.
In the entire cohort of patients, themeanVAI valuewas
1.9  0.8. Thirteen patients (54.2%) were classified as
having normal VAI (group A), whereas 11 (45.8%) had
highVAI (groupB).Noage, gender, orBMIdifferencewas
found between the two groups. Group B showed signifi-
cantly higher basal GH [32 (3.10–36) vs. 3.3 (1.20–9.70)
g/liter; P  0.018], AUCGH [3700 (525–4230) vs. 763
(345–997);P0.047], and IGF-IULN levels [2.40 (1.40–
3.50) vs. 1.61 (1.03–2.16); P  0.047] than group A,
whereas no difference was found in nadir GH, tumor size,
and duration of disease. Group B also showed a higher
prevalence of family history for diabetes (10 vs. 4%; P
0.005) (Table 2).
Using the National Cholesterol Education Program
Adult Treatment Panel III criteria (15), in the whole
cohort of patients, the metabolic syndrome (MS) was
found in six patients (25%). Specifically, 17 patients
(70.8%) had systolic hypertension, 13 (54.2%) had di-
astolic hypertension, seven (29.2%) were affected by
hypertriglyceridemia, 10 (41.7%) showed increased
WC, and seven (29.2%) had lowHDL-cholesterol levels
(Table 1). No difference in MS as a whole and in each
of its components was reported between the two
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groups, with the exception of the prevalence of systolic
hypertension, which was significantly higher in group B
(11 vs. 6%; P  0.006) (Table 2).
Six of 24 patients (25%) were classified as having nor-
mal glucose tolerance, 11 (45.8%) IFG, and seven
(29.2%) IGT. No patient had overt diabetes mellitus, ac-
cording to the medical guidelines of the American Asso-
ciation of Clinical Endocrinologists (16) (Table 1). No
difference in each category of glucose tolerancewas found
between the two groups, with the exception of a signifi-
cantly higher prevalence of IGT in group B (P  0.001).
No difference between the two groups of patients was
found in fasting glucose andHbA1c levels. The patients of
group B showed higher AUCCpeptide [769 (331–821) vs.
351 (279–421); P  0.018] and lower M value [1.65
(1.42–2.70) vs. 3.30 (3.14–4); P  0.001], DIo [0.39
(0.29–0.56) vs. 1.43 (0.44–2.50); P  0.006], and adi-
ponectin [4 (3.40–7.20) vs. 10.50 (9.10–15.95) g/ml;
P  0.001] than those of group A, whereas no difference
was found in leptin, TNF-, and IL-6 levels (Figs. 1 and2).
The differences in the clinical and biochemical features
between group A and group B are shown in Table 2.
In univariate analysis, VAI was found to be directly
correlated with age of patients (  0.408; P  0.048),
tumor volume (  0.638; P  0.001), basal GH ( 
0.622;P0.001), nadir ofGH(0.534;P0.007) and
AUCGH (0.603;P0.002) duringOGTT, IGF-IULN
(  0.618; P  0.001), and AUCCpeptide (  0.715;
0.001) and inversely correlated with M value ( 
0.818; P 0.001) and DIo (0.512; P 0.011). In
addition, a strongly significant inverse correlation was
found between VAI and adiponectin (  0.766; P 
0.001), whereas a significant direct correlation was
found between VAI and TNF- levels (  0.512; P 
0.010). No correlation was found with leptin and IL-6
(Table 3). In multivariate analysis, AUCGH (B 0.677;
P 0.001) and the family history for diabetes (B 0.386;
P  0.010) were the only variables independently as-
sociated with VAI (Table 4).
Discussion
We analyzed the visceral adipose function, insulin sensi-
tivity and secretion indexes, and adipocytokine levels in a
group of newly diagnosed acromegalic patients. Our data
show that VAI is independently influenced by GH levels.
Patients with high VAI show decreased insulin sensitivity
and seem to be less able to compensate the status of IR
through an adequate increased insulin secretion. In our
hypothesis, the lipotoxicity secondary to the lipolytic ac-
tion of GHmay be clinically expressed by VAI. In fact, in
acromegaly, a lipotoxic condition has been described.
Freda et al. (4) showed increased im adipose tissue despite
a reduction in visceral and sc adipose tissue in 24 adults
with active acromegaly compared with healthy subjects,
and this finding might be associated with GH-induced IR.
Our data showed a strong association between VAI and
the rate of peripheral glucoseutilization (Mvalue) as in the
general population (5). Furthermore, higher VAI showed
a strong independent association with both cardiovascu-
lar and cerebrovascular events and better predictive ca-
pacity for the onset of diabetes events than its individual
components (WC,BMI, TG, andHDL) (5, 17). This index
has already been studied in specific populations of pa-
tients; in those with genotype 1 chronic hepatitis C and in
those with nonalcoholic fatty liver disease, visceral adi-
pose dysfunction identified by a higher VAI score proved
to be independently associated with both steatosis and
necroinflammatory activity, and fibrosis (18, 19) in
women with polycystic ovary syndrome, VAI has proved
to be an easy and useful tool for the assessment of cardio-
TABLE 1. Clinical and biochemical features of all
acromegalic patients
Mean  SD or
n (%)
Age (yr) 54.9  13.6




Family history for diabetes 14 (58.3)
Duration of disease (months) 58  27.2
Tumor volume (mm3) 1310  660
Basal GH (g/liter) 13.8  14.6
Nadir GH (g/liter) 13.2  13.9
AUCGH 1779  1806
IGF-I (ULN) 2  0.8
MS 6 (25)
Increased WC 10 (41.7)
Hypertriglyceridemia 7 (29.2)
Low HDL-cholesterol 7 (29.2)
Increased SBP or specific treatment 17 (70.8)
Increased DBP or specific treatment 13 (54.2)





Fasting glucose (mmol/liter) 5.8  0.6
Fasting insulin (UI/ml) 19.1  16.7
M value (clamp) 2.69  0.88
AUCCpeptide (MMTT) 491  251
DIo 1.05  0.94
HbA1c (%) 5.7  0.4
VAI 1.9  0.8
Leptin (ng/ml) 8.15  8.52
Adiponectin (g/ml) 8.78  4.56
TNF- (ng/ml) 2.10  1.40
IL-6 (pg/ml) 1.63  0.59
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metabolic risk associated with the oligomenorrheic phe-
notype (20).
In our cohort of patients, VAI proved to be strongly
correlated with both GH and IGF-I levels and also with
tumor volume. As expected, patient age seems to be an
additional factor correlatedwithVAI, and these data seem
to be in agreement with those of Fieffe et al. (21), who
showed that age and BMI are significant risk factors of
type 2 diabetics.
In this view, older patients and those with higher hor-
monal levels have more severe visceral adipose dysfunc-
tion. Interestingly, the prevalence of high VAI in our ac-
romegalic patients was about twice that of the general
population (45.8 vs. 22.78%) (14). Surprisingly, no dif-
ference in MS as a whole and in each of its components,
except for systolic hypertension,was reportedbetween the
two groups of patients. A possible explanationmight lie in
the fact that the early stages of metabolic alterations are
not highlighted by the classic criteria, whereas VAI seems
to be able to show early signs of metabolic risk in patients
without overt MS, because the variables are treated as
continuous variables and not as dichotomous.
Regarding the increased systolic blood pressure in the
group of patients with high VAI, these patients also
showedhigherGHand IGF-I levels andhada lowerdegree
of insulin sensitivity. In our hypothesis, both the higher
insulin levels, known to be associated with increased
bloodpressure levels in the general population, and higher
GH levels, in concertwith IGF-I, couldhave amain impact
for the pathogenesis of sodium retention in acromegaly
(22, 23).
Although patients with high VAI were less insulin sen-
sitive, no significant difference in the glucose tolerance
categories, except for IGT, was reported between the two
groups of patients. This finding supports the hypothesis
that VAI shows the early signs of metabolic risk in pa-
tients, although a significant reduction in glucose toler-
ance has not yet occurred. Themajority of studies assessed
the insulin secretion rate by measurement of insulin levels
during OGTT, even though endogenous insulin secretion
TABLE 2. Clinical and biochemical features of patients grouped according to VAI into those with normal (group A)
or high VAI (group B)
Acromegalic patients with normal
VAI (group A) n  13 (54.2%)
Acromegalic patients with high
VAI (group B), n  11 (45.8%) P
Age (yr) 57 (46.50–69) 50 (45–62) 0.392
BMI (kg/m2) 27.8 (26–29.10) 28 (27–30) 0.331
Gender n (%) 0.217
Males 9 (69.2) 4 (36.4)
Females 4 (30.8) 7 (63.6)
Family history for diabetes n (%) 4 (30.8) 10 (90.9) 0.005
Duration of disease (months) 64 (26–76) 62 (15–90) 0.820
Tumor volume (mm3) 1200 (600–1425) 1800 (500–2400) 0.082
Basal GH (g/liter) 3.3 (1.20–9.70) 32 (3.10–36) 0.018
Nadir GH (g/liter) 5.50 (2–8.80) 19 (2.10–35) 0.082
AUCGH 763 (345–997) 3700 (525–4230) 0.047
IGF-I (ULN) 1.61 (1.03–2.16) 2.40 (1.40–3.50) 0.047
MS n (%) 3 (23.1) 3 (27.3) 1
Increased WC n (%) 4 (30.8) 6 (54.5) 0.408
Hypertriglyceridemia n (%) 3 (23.1) 4 (36.4) 0.659
Low HDL-cholesterol n (%) 3 (23.1) 4 (36.4) 0.659
Increased SBP or specific treatment n (%) 6 (46.2) 11 (100) 0.006
Increased DBP or specific treatment n (%) 8 (61.5) 5 (45.5) 0.431
Normal glucose tolerance n (%) 5 (38.5) 1 (9.1) 0.166
IFG n (%) 8 (61.5) 3 (27.3) 0.123
IGT n (%) 0 7 (63.6) 0.001
IFG  IGT 0 0
Diabetes mellitus 0 0
Fasting glucose (mmol/liter) 6.16 (5.58–6.49) 5.94 (4.72–6.33) 0.082
M value (clamp) 3.30 (3.14–4) 1.65 (1.42–2.70) 0.001
AUCCpeptide (MMTT) 351 (279–421) 769 (331–821) 0.018
DIo 1.43 (0.44–2.50) 0.39 (0.29–0.56) 0.006
HbA1c (%) 5.8 (5.45–5.90) 5.70 (5.10–6.70) 0.392
Leptin (ng/ml) 4.80 (2.80–18.45) 6.10 (2.40–9.60) 0.865
Adiponectin (g/ml) 10.50 (9.10–15.95) 4 (3.40–7.20) 0.001
TNF- (ng/ml) 1.30 (1.05–3.05) 3.30 (1.10–4) 0.082
IL-6 (pg/ml) 1.72 (1.35–2.07) 1.48 (1.06–1.80) 0.252
Unless indicated otherwise, results are shown as median (interquartile range).
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is assessed more efficiently by the measurement of C-pep-
tide,which is cosecretedwith insulin in aone-to-onemolar
ratio but, unlike insulin, undergoes poor first-pass clear-
ance by the liver. Measurement of C-peptide provides a
sensitive, well-accepted, and clinically validated assess-
ment of -cell function (24), and the gold standard mea-
sure of insulin secretion, represented by the measurement
of the C-peptide duringMMTT (12), has very rarely been
used to assess insulin secretion in acromegaly (25).
The higherAUCCpeptide in patientswith highVAImight
represent a compensatory mechanism to avoid clear glu-
cose tolerance worsening. For a better evaluation of the
ability of -cells to adequately compensate the insulin re-
sistance through increased insulin secretion, we also cal-
culated DIo, which has been shown to predict the devel-
opment of diabetes in adults (13). Patients with high VAI,
despite higher AUCCpeptide, showed lower DIo, demon-
strating inadequate insulin secretion relative to insulin
sensitivity degree.
Our group recently also showed that active acromeg-
aly is strongly associated with visceral adiposity dys-
function, and both somatostatin analogs and surgical
therapies are able to improve it, as demonstrated by the
significant VAI decrease after 12
months of therapy (26). However,
this study was limited by the lack of
data on adipocytokine assessment
and evaluation of insulin sensitivity
through the gold standard hyperinsu-
linemic-euglycemic clamp, because in-
sulin sensitivity has been examined us-
ing these methods in only a minority of
studies and in smaller cohorts of pa-
tients (27–30). We therefore analyzed
cytokine (leptin and adiponectin) and
proinflammatory (TNF- and IL-6) ac-
tivity to establish whether adipose
function plays a main role in deter-
mining metabolic alterations in acro-
megalic patients and whether this can
be adequately expressed by VAI. In
this regard, data regarding adipocy-
tokine levels in active acromegaly
available in the literature are contro-
versial, and the evaluation of a possi-
ble relationship between GH levels,
adipose function, and insulin sensitiv-
ity has been poorly investigated.
In our study, patients with high VAI
had lower adiponectin levels and con-
sequently less protection against both
IR and cardiometabolic risk (31–33). A
few years ago, a correlation between
leptin levels and BMI in acromegalic patients was found
but with controversial data (34, 35). In our opinion, the
leptin levels in our study did not show any significant
correlation with VAI because leptin should be considered
as an indirect index of overall adipose tissue, secreted by
adipocytes in proportion to total adipocyte tissue mass,
without a correlation with the quality of fat (36). In fact,
a correlationbetween leptin levels and sc and total adipose
tissue has been reported by other authors but without any
correlation with GH and IGF-I levels (4).
A condition of hypoadiponectinemia in acromegaly
wasdemonstrated (37), althoughRonchi et al. (38)didnot
show any significant correlation between adiponectin and
insulin sensitivity and resistance indexes. This is probably
because insulin homeostasiswas assessedby authors using
homeostasis model assessment of IR index and quantita-
tive insulin sensitivity check index and not the gold stan-
dard clamp (39).
In our patients, as expected, we found a positive cor-
relation between TNF- and VAI, suggesting a role of
TNF- as proinflammatory activity in visceral adipose
dysfunction and IR, as already reported in the general
FIG. 1. Insulin-sensitivity and insulin-secretion indexes in acromegalic patients in relation to
VAI. A, M value during euglycemic-hyperinsulinemic clamp in patients with normal and high
VAI; B, AUCC-peptide during MMTT in patients with normal and high VAI; C, DIo in patients
with normal and high VAI.
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population (40). In our study, we did not find any signif-
icant correlation between IL-6 and all parameters evalu-
ated. This datum is not surprising, because although a
great deal of evidence implicates IL-6 in the development
of IR, there is some conflicting evidence in the literature
(41).Thecontributionofvisceraladipose
tissue to circulating levels of IL-6 seems
modest (42), and the existing data in the
literature about the role of IL-6 in acro-
megaly are extremely few (43).
Aweakness of our study couldbe the
limitation of the range of recruited ac-
romegalic patients to a subgroup of pa-
tients with lower cardiovascular risk
than a totally unselected group of ac-
romegalicpatientswouldhave,because
in our cohort, we did not have overt
diabetic patients, although the data
about VAI on acromegalic patients
with different degrees of glucose abnor-
malities, including overt diabetes mel-
litus, are available in our previous pa-
per (24).
Another limitation of our study is
probably the lackofdirect dataonbody
composition, because MRI and com-
puted tomography, to date considered
the gold standard for the quantitative
evaluationofvisceral and scadipose tis-
sue (44), was not performed, because
these two methods are extremely ex-
pensive and too complicated for use in
routine practice.
We believe that it is important to
clarify that the application of VAI as a marker of cardio-
metabolic risk could have some limitations, mainly relat-
ing to the presence of variables in the model that may
change over time in relation to lifestyle and/or pharma-
cological treatment.Therefore,we suggest usingVAI as an
indicator of altered adipose function associated with car-
diometabolic riskbutwithout apredictive future role. Pro-
spective large-scale studies aiming to consider the possible
predictive valueofVAI regarding cardiovascular riskmust
necessarily take into account its variation over time.
In conclusion, in active acromegaly, VAI, directly and
independently influenced by GH levels and family history
FIG. 2. Adipocytokine levels in acromegalic patients in relation to VAI. A, Leptin levels in
patients with normal and high VAI; B, adiponectin levels in patients with normal and high
VAI; C, IL-6 levels in patients with normal and high VAI; D, TNF- levels in patients with
normal and high VAI.
TABLE 3. Correlation (univariate analysis) between VAI








Duration of disease 0.328 0.118
Tumor volume 0.638 0.001
Basal GH 0.622 0.001
AUCGH 0.603 0.002
GH nadir 0.534 0.007
IGF-I ULN 0.618 0.001
M value (clamp) 0.818 0.001






TABLE 4. Independent variables influencing VAI at




Age 0.165 0.010 0.238
AUCGH 0.677 0 0.001
IGF-I ULN 0.024 0.160 0.904
Family history for diabetesa 0.386 0.190 0.010
a Categorical variable coded to binary (dummy) variables: no family
history  0; family history  1.
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for diabetes, may reflect a condition of cardiometabolic
risk, characterized by altered production of adipocyto-
kines, IR, and inadequate insulin secretion. Therefore, the
routine use of this simple tool can show a degree of early
cardiometabolic risk even in cases in which the overt MS
and glucose abnormalities have not yet appeared.
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